Randomized, multicenter, phase 3 study of 1st-line irinotecan+5FU/folinic acid vs cisplatin+5FU in patients with advanced gastric cancer

Pozzo, C.Zaluski, J.Dank, M.Barone, C.Valvere, V.Peschel, C.Wenczl, M.Goker, E.Bugat, R.2019-10-272019-10-2720051359-6349https://hdl.handle.net/11454/39124eninfo:eu-repo/semantics/closedAccessRandomized, multicenter, phase 3 study of 1st-line irinotecan+5FU/folinic acid vs cisplatin+5FU in patients with advanced gastric cancer - quality of life analysisConference Object32204204WOS:000247564800696Q2